Detail akcie Roche Holding AG Depository Receipt online

Business Summary: Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Roche Holding AG (ADR) revenues decreased 7% to SF58.72B. Net income decreased 7% to SF11.5B. Revenues reflect Diagnostics segment decrease of 20% to SF14.1B, Chugai segment decrease of 24% to SF3.75B, Japan segment decrease of 23% to SF4.37B, Rest of Asia segment decrease of 10% to SF8.89B, United States segment decrease of 3% to SF27.18B.